Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $40.01 (market cap $139.69M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 7× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 62 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GPTY | MRVI | |
|---|---|---|
Market Cap | $139.69M | $977.37M |
Volume | 81,745 | 2,742,564 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $9.00 |
52-Week Low | $34.73 | $2.83 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY, a US stock, trades at $42.44, up 0.05% in the last 24 hours. The technical outlook is bearish based on moving averages, with key support at $42 and resistance at $43. Recent news highlights the ETF's weekly dividend distributions and a Seeking Alpha article from August 2026 rating it a Buy for high AI-driven income, citing its covered call spread strategy.
The outlook for GPTY is mixed, with a high-yield income opportunity from consistent dividends but tempered by bearish technical signals and limited fundamental data. Risks include market volatility and dependence on options strategies, while institutional interest remains a potential catalyst.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
